▸ As of December 31, 2025, we were not aware of any tariffs impacting our operations.· · · ● 1 ▸ In 2025, following the completion of the NXP800 Phase 1b study, we decided to cease the clinical development of NXP800 as we assess possible next steps, if any, in the development of the compound.· · · ● 1 ▸ Tariffs and other trade measures could adversely affect our business, results of operations, financial position and cash flows.· · · ● 1 ▸ We currently hold a license to certain intellectual property relating to NXP900, including its composition of matter and to other compounds that inhibit the SRC and YES1 kinases.· · · ● 1 ▸ Although we maintain workers’ compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against· · ● · 1 ▸ If we fail to satisfy the continuing listing requirements of NASDAQ, such as the corporate governance, stockholders’ equity or minimum closing bid price requirements, NASDAQ may take steps to delist our common stock. Such a delisting· · ● · 1 ▸ Our pipeline product candidates, NXP800 and NXP900, are both in clinical development. Both product candidates will require additional preclinical and clinical studies, regulatory review and approval, substantial investment, access to· · ● · 1 ▸ Recent efforts by the Trump Administration to reduce government spending include reductions in FDA’s workforce.· · ● · 1 ▸ The use of precision medicines as a potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers, and others in the medical community. We cannot· · ● · 1 ▸ This may impact the FDA’s ability to approve current or future products and could delay regulatory approval of our· · ● · 1 ▸ SEC or other regulatory authorities, which would require additional financial and management resources, costly litigation or a loss of public confidence in our internal control, which could have an adverse effect on the market price of our stock.· ● · · 1 ▸ Major public health issues, and specifically the pandemic caused by the coronavirus COVID-19 outbreak, could have an adverse effect on our clinical trials, financial condition, results of operations, and other aspects of our business.● ● · · 2 ▸ Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval for our current or future product candidates.● ● ● · 3 ▸ There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas.● ● · ● 3 ▸ A variety of risks associated with marketing our current or future product candidates internationally could materially adversely affect our business.● ● ● ● 4 ▸ Adverse pricing limitations may hinder our ability to recoup our investment in one or more of our current or future product candidates, even if any such current or future product candidate we may develop obtains marketing approval.● ● ● ● 4 ▸ Changes to patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.● ● ● ● 4 ▸ Clinical drug development involves a lengthy and expensive process with uncertain outcomes, clinical trials are difficult to design and implement, and any of our clinical trials could produce unsuccessful results or fail at any stage in the process.● ● ● ● 4 ▸ Denial of or delay in our receipt of required regulatory approvals may prevent or delay commercialization of our current or future product candidates and our ability to generate revenue may be materially impaired.● ● ● ● 4 ▸ Difficulty in enrolling patients could delay or prevent clinical trials of our current or future product candidates.● ● ● ● 4 ▸ Healthcare legislative measures and changes in policies, funding, staffing and leadership at the FDA and other agencies could hinder or prevent the commercial success of our products.● ● ● ● 4 ▸ If any of our current or future product candidates do not achieve broad market acceptance among physicians, patients, healthcare payors and the medical community, the revenues from any such current or future product candidate may be limited.● ● ● ● 4 ▸ If equity research analysts do not publish research or reports about our business or if they publish negative evaluations of or downgrade our Common Stock, the price of our Common Stock could decline.● ● ● ● 4 ▸ If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.● ● ● ● 4 ▸ If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our marks of interest and our business may be adversely affected.● ● ● ● 4 ▸ If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates.● ● ● ● 4 ▸ If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.● ● ● ● 4 ▸ If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our discovery and preclinical development programs or any future commercialization efforts.● ● ● ● 4 ▸ If we do not obtain patent term extension and data exclusivity for any of our current or future product candidates we may develop, our business may be materially harmed.● ● ● ● 4 ▸ If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.● ● ● ● 4 ▸ In the United States, there have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations and the future results of operations of our potential customers.● ● ● ● 4 ▸ Our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or third parties’ cybersecurity.● ● ● ● 4 ▸ Our development approach may never lead to marketable products.● ● ● ● 4 ▸ Our failure to meet the continuing listing requirements of the NASDAQ Capital Market could result in a de-listing of our securities.● ● ● ● 4 ▸ Our growth is subject to economic and political conditions.● ● ● ● 4 ▸ Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.● ● ● ● 4 ▸ Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval.● ● ● ● 4 ▸ Provisions in our certificate of incorporation, our bylaws, and Delaware law may discourage, delay, or prevent a change in control of our Company or changes in our management and, as a result, depress the trading price of our stock.● ● ● ● 4 ▸ Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our current or future technologies or product candidates.● ● ● ● 4 ▸ group Risks Related to Commercial Activities● ● ● ● 4 ▸ group Risks Related to Government Regulation● ● ● ● 4 ▸ group Risks Related to Managing Growth and Employee Matters● ● ● ● 4 ▸ group Risks Related to Our Finances and Capital Requirements● ● ● ● 4 ▸ group Risks Related to Ownership of our Common Stock● ● ● ● 4 ▸ group Risks Related to our Intellectual Property● ● ● ● 4 ▸ group Risks Related to our Reliance on Third Parties● ● ● ● 4 ▸ group Risks Related to the Development of our Product Candidates● ● ● ● 4 ▸ The FDA and comparable foreign regulatory authorities may not accept data from any preclinical or clinical trials we may conduct in foreign countries.● ● ● ● 4 ▸ The FDA’s acceptance of data generated for patients recruited outside the United States from clinical trials conducted in whole or in part outside the United States may be subject to certain conditions, if accepted at all.● ● ● ● 4 ▸ Third-party claims of intellectual property infringement, misappropriation or other violations may be costly and time consuming and may prevent or delay our product discovery and development efforts.● ● ● ● 4 ▸ We do not intend to pay dividends on our Common Stock in the foreseeable future, so any returns will be limited to the value of our stock, which may be volatile.● ● ● ● 4 ▸ We do not know whether an active, liquid and orderly trading market will develop for our Common Stock or what the market price of our Common Stock will be and, as a result, it may be difficult for you to sell your shares of our Common Stock.● ● ● ● 4 ▸ We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.● ● ● ● 4 ▸ We may be subject to claims challenging the inventorship or ownership of our intellectual property, including any patents we may own or in-license currently or in the future.● ● ● ● 4 ▸ We may not be able to submit IND applications to commence additional clinical trials based on the timelines that we expect, and even if we are able to do so, the FDA may not permit us to proceed.● ● ● ● 4 rw ▸ We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance activities and initiatives.● ● ● ● 4 ▸ We will need to grow the size of our organization, and we may experience difficulties in managing this growth.● ● ● ● 4 
